SG11201907084VA - Pharmaceutical compositions for combination therapy - Google Patents
Pharmaceutical compositions for combination therapyInfo
- Publication number
- SG11201907084VA SG11201907084VA SG11201907084VA SG11201907084VA SG11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- loos
- pct
- danel
- leonard
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
WO 18/ 15408 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT ill mu °mons °nolo OH 100 Ho oinio oimIE (10) International Publication Number WO 2018/154081 Al (51) International Patent Classification: A61K 31/41 78 (2006.01) A61K 31/192 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/EP2018/054588 (22) International Filing Date: 23 February 2018 (23.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305213.5 24 February 2017 (24.02.2017) EP (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene Avinee, 59120 LOOS (FR). (72) Inventors: DESCAMPS, Emeline; 9 me Leonard Danel, 59120 LOOS (FR). WALCZAK, Robert; Residence Parc d'Isly, 13B me Delezenne, 59000 LILLE (FR). BE- LANGER, Carole; 3 Allee du Verger, 59910 BONDUES (FR). NOEL, Benoit; 9 me Leonard Danel, 59120 Loos (FR). (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand, 75002 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY (57) : The present invention relates to a combination of active ingredients for use in the treatment of diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305213 | 2017-02-24 | ||
| PCT/EP2018/054588 WO2018154081A1 (en) | 2017-02-24 | 2018-02-23 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907084VA true SG11201907084VA (en) | 2019-09-27 |
Family
ID=58231557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907084VA SG11201907084VA (en) | 2017-02-24 | 2018-02-23 | Pharmaceutical compositions for combination therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11590108B2 (en) |
| EP (1) | EP3585384A1 (en) |
| JP (1) | JP2020510651A (en) |
| KR (1) | KR102633249B1 (en) |
| CN (1) | CN110418641A (en) |
| AU (1) | AU2018223976B2 (en) |
| BR (1) | BR112019017314A2 (en) |
| CA (1) | CA3051977A1 (en) |
| EA (1) | EA201991990A1 (en) |
| IL (1) | IL268708B (en) |
| MX (1) | MX2019009909A (en) |
| PH (1) | PH12019501820A1 (en) |
| SG (1) | SG11201907084VA (en) |
| WO (1) | WO2018154081A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4233910A3 (en) * | 2016-03-31 | 2024-01-17 | Genfit | Methods of treatment of cholestatic diseases |
| US12053445B2 (en) * | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2206702T3 (en) | 2001-08-08 | 2012-02-13 | Tobira Therapeutics Inc | Bicyclic compound, preparation and use thereof |
| FR2841900B1 (en) | 2002-07-08 | 2007-03-02 | Genfit S A | NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES |
| KR101962209B1 (en) * | 2009-11-26 | 2019-03-26 | 장피트 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| JP6217938B2 (en) * | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | Bile acid recirculation inhibitors for the treatment of cholestatic liver disease in children |
| SG11201607859SA (en) * | 2014-03-21 | 2016-10-28 | Tobira Therapeutics Inc | Cenicriviroc for the treatment of fibrosis |
| RU2723559C2 (en) * | 2014-09-12 | 2020-06-16 | Тобира Терапьютикс, Инк. | Combined therapy with application of cenicriviroc for fibrosis treatment |
| JP2018532720A (en) | 2015-09-16 | 2018-11-08 | トビラ セラピューティクス， インコーポレイテッド | Senicribiroc combination therapy for the treatment of fibrosis |
| EP4233910A3 (en) | 2016-03-31 | 2024-01-17 | Genfit | Methods of treatment of cholestatic diseases |
| CN109152760B (en) | 2016-04-11 | 2022-09-23 | 基恩菲特公司 | Methods of treating cholestatic and fibrotic diseases |
| JOP20190040A1 (en) * | 2016-09-14 | 2019-03-10 | Novartis Ag | Combination of fxr agonists |
| SG11201906041QA (en) | 2017-01-27 | 2019-08-27 | Genfit | Pharmaceutical compositions for combination therapy |
-
2018
- 2018-02-23 AU AU2018223976A patent/AU2018223976B2/en active Active
- 2018-02-23 JP JP2019546127A patent/JP2020510651A/en active Pending
- 2018-02-23 CN CN201880013686.4A patent/CN110418641A/en active Pending
- 2018-02-23 KR KR1020197027007A patent/KR102633249B1/en active IP Right Grant
- 2018-02-23 SG SG11201907084VA patent/SG11201907084VA/en unknown
- 2018-02-23 WO PCT/EP2018/054588 patent/WO2018154081A1/en unknown
- 2018-02-23 CA CA3051977A patent/CA3051977A1/en active Pending
- 2018-02-23 US US16/485,025 patent/US11590108B2/en active Active
- 2018-02-23 BR BR112019017314A patent/BR112019017314A2/en not_active Application Discontinuation
- 2018-02-23 EA EA201991990A patent/EA201991990A1/en unknown
- 2018-02-23 EP EP18705945.6A patent/EP3585384A1/en not_active Withdrawn
- 2018-02-23 MX MX2019009909A patent/MX2019009909A/en unknown
-
2019
- 2019-08-06 PH PH12019501820A patent/PH12019501820A1/en unknown
- 2019-08-14 IL IL268708A patent/IL268708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019009909A (en) | 2019-10-14 |
| KR20190119097A (en) | 2019-10-21 |
| AU2018223976B2 (en) | 2023-08-17 |
| CN110418641A (en) | 2019-11-05 |
| EP3585384A1 (en) | 2020-01-01 |
| US11590108B2 (en) | 2023-02-28 |
| CA3051977A1 (en) | 2018-08-30 |
| AU2018223976A1 (en) | 2019-09-05 |
| IL268708A (en) | 2019-10-31 |
| IL268708B (en) | 2022-05-01 |
| PH12019501820A1 (en) | 2020-09-14 |
| US20190388394A1 (en) | 2019-12-26 |
| BR112019017314A2 (en) | 2020-04-14 |
| WO2018154081A1 (en) | 2018-08-30 |
| JP2020510651A (en) | 2020-04-09 |
| EA201991990A1 (en) | 2020-04-07 |
| KR102633249B1 (en) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201909168VA (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases |